|Slideshows|March 6, 2015

Confronting America’s Smoking Pandemic, Part 1: 1939–1966

Ahead of the World Tobacco Congress, Dr. Alan Blum and Cancer Network have partnered to assemble a four-part slideshow series addressing the history of America’s smoking pandemic. Part 1 examines the early evidence linking smoking with cancer.

Confronting America’s Smoking PandemicPart 1: From Early Evidence to Global Battle, 1939â1966Part 2: An Era of Activism, 1967â1985Part 3: Regulation, Legislation, Litigation, 1986â1999Part 4: Failures and Successes 2000â2016

References:

1. Ochsner A, DeBakey M. Primary pulmonary malignancy: treatment by total pneumonectomy; analysis of 79 collected cases and presentation of 7 personal cases. Surg Gynecol Obstet. 1939;68:435-51.

2. Ochsner Health System. Living the legacy: who was Alton Ochsner and why are we living his legacy? January 18, 2011.

3. Ventura HO. Alton Ochsner, MD: physician. Ochsner J. 2002;4:48-52.

4. Nelson J. Advertising bans, US. EH.Net Encyclopedia. Whaples R, editor. May 20, 2004.

5. Justia US Supreme Court. Valentine v. Chrestensen, 316 U.S. 52 (1942).

6. Wynder EL, Graham EA. Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma; a study of 684 proved cases. J Am Med Assoc. 1950;143:329-36.

7. Levin ML, Goldstein H, Gerhardt PR, et al. Cancer and tobacco; a preliminary report. J Am Med Assoc. 1950;143:336-8.

8. Doll R, Hill AB. Smoking and carcinoma of the lung. Preliminary report. Br Med J. 1950;2:739-48.

9. Ochsner A, DeCamp PT, DeBakey ME, Ray CJ. Bronchogenic carcinoma; its frequency, diagnosis, and early treatment. J Am Med Assoc. 1952;148:691-7.

10. Norr R. Cancer by the carton. Christian Herald, October 1952; a condensed version was published in Reader’s Digest by the Reader’s Digest Association, Pleasantville, New York. December 1952, p. 7,8. Available from the Legacy Tobacco Documents Library, University of California, San Francisco.

11.A frank statement to cigarette smokers. Tobacco Industry Research Committee, New York, NY. [Image shows advertisement as it was printed in the Indianapolis News, January 4, 1954.]

12. Hammond EC, Horn D. Smoking and death rates-report on forty-four months of follow-up of 187,783 men. J Am Med Assoc. 1958;166:1294-308.

13. Burney LE. Smoking and lung cancer. A statement of the public health service. J Am Med Assoc. 1959;171:1829-37.

14. Welcome to the five-day plan to stop smoking: even to better living. General Conference of Seventh-Day Adventists. Washington, DC. 1962. p. 52.

15. McFarland JW, Folkenberg EJ. How to stop smoking in five days. Englewood Cliffs, NJ: Prentice-Hall; 1964. p. 92.

16. McFarland JW, Gimbel HW, Donald WAJ, Folkenberg EJ. The five-day program to help individuals stop smoking. Conn Med. 1964;28:885-90.

17.

Smoking and health: summary of a report of The Royal College of Physicians of London on smoking in relation to cancer of the lung and other diseases

. London: Pitman Publishing Co. Ltd.; 1962.

18. Neuberger MB. Smoke screen: tobacco and the public welfare. Englewood Cliffs, NJ: Prentice-Hall; 1963. p. 151.

19. US Public Health Service, Office of the Surgeon General, Surgeon General’s Advisory Committee on Smoking and Health. Smoking and health: report of the Advisory Committee to the Surgeon General of the Public Health Service. PHS publication 1103. 1964. Subsequent reports from the Surgeon General.

20. Tobacco Control Legal Consortium. Federal Trade Commission and Tobacco.

Federal Cigarette Labeling and Advertising Act (15 U.S.C. 1333).

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!

Confronting America’s Smoking Pandemic, Part 1: 1939–1966

References:

Newsletter

Related Content

Anti-TIGIT Combination Therapy Yields Positive Survival in Gastric Cancers

Translating CLL Trial Success to Real-World Treatment Application

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Consolidating Cancer Care Information in a Single Electronic Database

Niraparib Combo Boosts rPFS in Metastatic HRR-Altered CSPC

Latest CME

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | Tennessee

Examining the Role of ctDNA in the Management of Breast Cancer: Latest Evidence and Future Directions

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | Arizona

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Tumor Board: Advances in Managing EGFR-Mutant NSCLC—Applying Evidence Across the Disease Continuum

Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | Iowa

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | New York

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | Minnesota

20th Annual New York Lung Cancers Symposium®

Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board

PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?

Advances In™: Taking R/R B-Cell ALL Management to the Next Level With New CAR T Approval

Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances

Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies

Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care

Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer

Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials

Annual Hematology Meeting: Preceding the 67th ASH Annual Meeting and Exposition

Breast Cancer Symposia in San Antonio

Burst CME™: How is the Newly Approved CAR T-Cell Therapy Impacting R/R B-Cell ALL Management?

Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care

Epithelioid Sarcoma: Applying Clinical Updates to Real Patient Cases

Collaborating Across the Continuum®: Identifying and Treating Epithelioid Sarcoma

Mastering Epithelioid Sarcoma: Enhancing Diagnostic Precision and Tailoring Treatment Strategies

Clinical Showcase™: Selecting the Best Next Steps for a Patient with Epithelioid Sarcoma

Inaugural Brain & Spine Metastases Conference: Evolving Practice and Emerging Therapies

2nd Annual Hawaii Cancer Conference

Medical Crossfire®: Bridging Evidence to Practice in AML…Updates on FLT3, IDH1/2, Maintenance, Combos, and Clinical Trials

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers

19th Annual New York GU Cancers Congress™

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

11th Annual School of Gastrointestinal Oncology® (SOGO®)

Addressing Unmet Needs in HER2+ Metastatic BTC

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Proactive Adverse Event Management for HER2+ BTC Treatments

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Establishing the Rationale for ADC and ICI Combinations in TNBC

Breaking Down the Rationale for Targeting TROP2 in TNBC

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Cross-Disease Integration of Immunotherapy Innovations

Optimizing Treatment for Biliary Tract Cancers

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer